Treats anemia due to Chronic Kidney Disease (CKD). Sold as Epogen/Procrit. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Epoetin Alfa (sold as Epogen/Procrit), first approved Jun 1, 1989, with 6 new uses approved and 0 published complete response letters.
| Procrit | Part D | $147M | -6% | 22,442 |
| Epogen (J0885) | Part B | $40.5M | -25% | 22,842 |
| Epogen | Part D | $7.7M | -5% | 4,139 |
| Epogen (Q4081) | Part B | $6K | +19% | 15 |
| Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsAnemia Associated With Chronic Kidney Disease · Chinese University of Hong Kong | Phase 2 | Recruiting | Oct 2, 2026 |
| Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing DialysisChronic Kidney Disease (Stages 3b-5), Anemia Associated With Chronic Kidney Disease · Services Hospital, Lahore | Not applicable | Not yet recruiting | Aug 10, 2026 |
| Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological MalignanciesLuspatercept, Epoetin · Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 | Not yet recruiting | Jun 9, 2026 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center HemodialysisAnemia Associated With Chronic Kidney Disease · Geoff Block | Phase 3 | Not yet recruiting | May 4, 2026 |
| Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis PatientsRenal Anemia · Mackay Memorial Hospital | Phase 4 | Not yet recruiting | Apr 17, 2026 |
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Myelodysplastic Syndrome · National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Mar 11, 2026 |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood TransfusionsMyelodysplastic Syndrome, Anemia · Takeda | Phase 3 | Recruiting | Feb 20, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 1, 1989 | Epogen/ProcritBLA 103234 · New molecular entity | Amgen | 35 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Amgen